Aamer Aleem
YOU?
Author Swipe
View article: Omics and artificial intelligence integration for stratifying blast crisis CML using COSMIC signatures and pan-cancer precision drug repurposing
Omics and artificial intelligence integration for stratifying blast crisis CML using COSMIC signatures and pan-cancer precision drug repurposing Open
BACKGROUND Although chronic-phase chronic myeloid leukemia (CP-CML) is treatable and nearly curable in about 50% of patients, accelerated-phase chronic myeloid leukemia (AP-CML) shows concerning drug resistance, while blast crisis chronic …
View article: Survival and Outcome of Patients with Diffuse Large B-cell Lymphoma According to the Central Nervous System–International Prognostic Index
Survival and Outcome of Patients with Diffuse Large B-cell Lymphoma According to the Central Nervous System–International Prognostic Index Open
Background: Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma. Several prognostic scores exist in DLBCL, including the International Prognostic Index (IPI). More recently, a modification of the IPI that …
View article: Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Myeloid Leukemias
Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Myeloid Leukemias Open
Tyrosine kinase inhibitors (TKIs) have transformed outcomes in chronic myeloid leukemia (CML) and FLT3-mutated acute myeloid leukemia (AML), yet durable remissions are curtailed by the emergence of drug resistance. This review summarizes t…
View article: Comparison of Pain, Cosmetic Outcomes and Early Restoration of Breast Feeding in Multiple Percutaneous Needle Aspiration Vs Incision and Drainage for Small Breast Abscess Management
Comparison of Pain, Cosmetic Outcomes and Early Restoration of Breast Feeding in Multiple Percutaneous Needle Aspiration Vs Incision and Drainage for Small Breast Abscess Management Open
Breast abscesses disrupt postpartum women's well-being, hindering breastfeeding and affecting cosmetic outcomes. Traditional incision and drainage (ID) often causes significant discomfort and suboptimal aesthetics. Multiple percutaneous ne…
View article: Low Rate of Central Nervous System Relapse of Diffuse Large B-Cell Lymphoma Despite Limited Use of Intrathecal Prophylaxis
Low Rate of Central Nervous System Relapse of Diffuse Large B-Cell Lymphoma Despite Limited Use of Intrathecal Prophylaxis Open
CNS relapse of DLBCL was uncommon in this patient population. Low incidence of CNS relapse despite limited use of IT prophylaxis may suggest adequacy of IT prophylaxis in these patients.
View article: Outcomes of Patients with Hematological Malignancies Admitted to the Intensive Care Unit at a Tertiary Care Center in Saudi Arabia
Outcomes of Patients with Hematological Malignancies Admitted to the Intensive Care Unit at a Tertiary Care Center in Saudi Arabia Open
Background: Patients with hematological malignancies (HM) are at risk for complications, including neutropenia and admission to the intensive care unit (ICU). Granulocyte colony-stimulating factors (GCSF) can accelerate progenitor cells’ p…
View article: Employing Integrated Omics, Artificial Intelligence and Machine learning Tools for Refined Stratification of Blast Crisis CML Patients via Genetic clustering and COSMIC Mutational Signatures: A Practical Framework for Precision Repurposing of FDA/EMA-Approved Anti-Cancer Drugs in Refractory Cancers post-COVID19
Employing Integrated Omics, Artificial Intelligence and Machine learning Tools for Refined Stratification of Blast Crisis CML Patients via Genetic clustering and COSMIC Mutational Signatures: A Practical Framework for Precision Repurposing of FDA/EMA-Approved Anti-Cancer Drugs in Refractory Cancers post-COVID19 Open
View article: Metabolic and Nutritional Mutation Signatures Drive Early Progression of Chronic Myeloid Leukemia: A Whole-Exome and AI-Guided Precision Framework
Metabolic and Nutritional Mutation Signatures Drive Early Progression of Chronic Myeloid Leukemia: A Whole-Exome and AI-Guided Precision Framework Open
View article: Investigations on druggable gene mutations related to AML/ALL lineage genes in Advanced Phases of CML: Implications in patient-tailored therapy of blast crisis CML in TKI era
Investigations on druggable gene mutations related to AML/ALL lineage genes in Advanced Phases of CML: Implications in patient-tailored therapy of blast crisis CML in TKI era Open
Background Chronic Myeloid Leukemia (CML) is a myeloproliferative stem cell malignancy. Chronic Phase CML (CP-CML) is treatable with overall survival equivalent to the general population. Nevertheless, a proportion of CP-CML progresses to …
View article: Clinical Validation of the Somatic FANCD2 Mutation (c.2022-5C>T) as a Novel Molecular Biomarker for Early Disease Progression in Chronic Myeloid Leukemia: A Case–Control Study
Clinical Validation of the Somatic FANCD2 Mutation (c.2022-5C>T) as a Novel Molecular Biomarker for Early Disease Progression in Chronic Myeloid Leukemia: A Case–Control Study Open
Background: Chronic myeloid leukemia (CML) results from chromosomal translocation t(9;22) leading to the formation of the BCR-ABL fusion oncogene. CML has three stages: the chronic phase (CP), the accelerated phase (AP), and the blast cris…
View article: COMPARISON OF THE OUTCOME OF MONOPOLAR VERSUS BIPOLAR DIATHERMY USE DURING TRANSURETHRAL RESECTION OF PROSTATE
COMPARISON OF THE OUTCOME OF MONOPOLAR VERSUS BIPOLAR DIATHERMY USE DURING TRANSURETHRAL RESECTION OF PROSTATE Open
Monopolar transurethral resection of the prostate (M-TURP) remains a widely used surgical modality for treating benign prostatic hyperplasia (BPH). However, bipolar TURP (B-TURP), which uses isotonic saline as an irrigant, may reduce the r…
View article: A retrospective case-control study for Clinical Validation of mutated ZNF208 as a novel biomarker of fatal blast crisis in Chronic Myeloid Leukemia
A retrospective case-control study for Clinical Validation of mutated ZNF208 as a novel biomarker of fatal blast crisis in Chronic Myeloid Leukemia Open
The hallmark of Chronic Myeloid Leukemia (CML) is Philadelphia chromosome t(9:22), which leads to formation of BCR-ABL1 fusion oncogene. BCR-ABL1 induces genetic instability, causing the progression of chronic myeloid leukemia (CML) from t…
View article: Integrated Genomic Analysis Identifies ANKRD36 Gene as a Novel and Common Biomarker of Disease Progression in Chronic Myeloid Leukemia
Integrated Genomic Analysis Identifies ANKRD36 Gene as a Novel and Common Biomarker of Disease Progression in Chronic Myeloid Leukemia Open
Background: Chronic Myeloid Leukemia (CML) is initiated in bone marrow due to chromosomal translocation t(22;9) leading to fusion oncogene BCR-ABL. Targeting BCR-ABL by tyrosine kinase inhibitors (TKI) have changed fatal CML into an almost…
View article: EXPLORING DRUG POTENTIAL OF MYELOID/LYMPHOID LINEAGE GENE MUTATIONS IN ADVANCED-PHASE CML USING DRUG DISCOVERY TOOLS: INSIGHTS FOR PRECISION ONCOLOGY IN BLAST CRISIS CML IN THE POST-COVID-19 ERA
EXPLORING DRUG POTENTIAL OF MYELOID/LYMPHOID LINEAGE GENE MUTATIONS IN ADVANCED-PHASE CML USING DRUG DISCOVERY TOOLS: INSIGHTS FOR PRECISION ONCOLOGY IN BLAST CRISIS CML IN THE POST-COVID-19 ERA Open
View article: ADVANCES AND CHALLENGES IN WHEAT GENETICS AND BREEDING FOR GLOBAL FOOD SECURITY
ADVANCES AND CHALLENGES IN WHEAT GENETICS AND BREEDING FOR GLOBAL FOOD SECURITY Open
This exploration delves into the pivotal realm of "Advances and Challenges in Wheat Genetics and Breeding for Global Food Security." Tracing the historical perspectives of wheat genetics from ancient agricultural practices to modern breedi…
View article: Leukaemia Cutis
Leukaemia Cutis Open
Null.
View article: Bleeding Diathesis as the Initial Presentation of Chronic Myeloid Leukemia: A Case Series
Bleeding Diathesis as the Initial Presentation of Chronic Myeloid Leukemia: A Case Series Open
View article: RETRACTED ARTICLE: Association Of BCR-ABL Alternative Splice Variants with Disease Progression, Treatment Response and Survival in Chronic Myeloid Leukemia Patients Treated with Firstline imatinib Monotherapy
RETRACTED ARTICLE: Association Of BCR-ABL Alternative Splice Variants with Disease Progression, Treatment Response and Survival in Chronic Myeloid Leukemia Patients Treated with Firstline imatinib Monotherapy Open
Background: Alternative RNA splicing has diverse biological effects in heath as well as disease. It also contributes to cancer onset and progression. Chronic Myeloid Leukemia (CML) results due to BCR-ABL fusion oncogene that is created due…
View article: Low Incidence of Central Nervous System (CNS) Relapse of Diffuse Large B-Cell Lymphoma despite Limited Use of Intrathecal Prophylaxis
Low Incidence of Central Nervous System (CNS) Relapse of Diffuse Large B-Cell Lymphoma despite Limited Use of Intrathecal Prophylaxis Open
Objective: Diffuse large B cell lymphoma (DLBCL) is the commonest sub type of non-Hodgkin's lymphoma (NHL) accounting for 30–50 % of NHL cases. Around 2% to 10% of patients with diffuse large B-cell lymphoma (DLBCL) experience central nerv…
View article: The Menace of Medical Fake News
The Menace of Medical Fake News Open
View article: Survival and Epidemiologic Trends of Lymphomas in Saudi Arabia
Survival and Epidemiologic Trends of Lymphomas in Saudi Arabia Open
Background: The current trends in lymphoma cases from Saudi Arabia and their long-term survival are unknown. This study was conducted to evaluate the trends of lymphoma diagnoses and survival from a major tertiary care hospital in Saudi Ar…
View article: [Retracted] Knowledge and Behavior toward Venous Thromboembolism Event Prophylaxis and Treatment Protocols among Medical Interns in Riyadh
[Retracted] Knowledge and Behavior toward Venous Thromboembolism Event Prophylaxis and Treatment Protocols among Medical Interns in Riyadh Open
Objective . This study was aimed at evaluating the knowledge and behavior toward venous thromboembolism (VTE) prophylaxis among medical interns. Methods . This is a questionnaire‐based cross‐sectional observational cohort study of medical …
View article: Integrated Genomic Analysis Identifies ANKRD36 Gene as a Novel and Common Biomarker of Disease Progression in Chronic Myeloid Leukemia
Integrated Genomic Analysis Identifies ANKRD36 Gene as a Novel and Common Biomarker of Disease Progression in Chronic Myeloid Leukemia Open
Background: Chronic myeloid leukemia (CML) is initiated in bone marrow due to chromosomal translocation t(9;22) leading to fusion oncogene BCR-ABL. Targeting BCR-ABL by tyrosine kinase inhibitors (TKIs) has changed fatal CML into an almost…
View article: Integrated Genomic Analysis Identifies ANKRD36 Gene as a Novel and Common Biomarker of Disease Progression in Chronic Myeloid Leukemia
Integrated Genomic Analysis Identifies ANKRD36 Gene as a Novel and Common Biomarker of Disease Progression in Chronic Myeloid Leukemia Open
Background: Chronic Myeloid Leukemia (CML) is initiated in bone marrow due to chromosomal translocation t(22;9) leading to fusion oncogene BCR-ABL. Targeting BCR-ABL by tyrosine kinase inhibitors (TKI) have changed fatal CML into an almost…
View article: The Impact of Covid-19: A Pandemic after Effects in Institutions of Pakistan
The Impact of Covid-19: A Pandemic after Effects in Institutions of Pakistan Open
The outbreak of COVID-19 was identified as a causative agent of severe acute respiratory syndrome 1. The first case origin that was highlighted in Hubei province of China in December 2019. Nowadays, the further spread shows its presence ar…
View article: Assessment of anti-factor Xa activity in critically ill COVID-19 patients receiving three different anticoagulation regimens
Assessment of anti-factor Xa activity in critically ill COVID-19 patients receiving three different anticoagulation regimens Open
Introduction: Critically ill COVID-19 patients are at increased risk of thrombosis with an enhanced risk of bleeding. We aimed to explore the role of anti-factor Xa levels in optimizing the high-intensity anticoagulation’s safety and effic…
View article: sj-docx-1-smo-10.1177_20503121211049931 – Supplemental material for Assessment of anti-factor Xa activity in critically ill COVID-19 patients receiving three different anticoagulation regimens
sj-docx-1-smo-10.1177_20503121211049931 – Supplemental material for Assessment of anti-factor Xa activity in critically ill COVID-19 patients receiving three different anticoagulation regimens Open
Supplemental material, sj-docx-1-smo-10.1177_20503121211049931 for Assessment of anti-factor Xa activity in critically ill COVID-19 patients receiving three different anticoagulation regimens by Mohammed A Hamad, Shereen A Dasuqi, Aamer Al…
View article: Discovery and Protein Modeling Studies of Novel Compound Mutations Causing Resistance to Multiple Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Discovery and Protein Modeling Studies of Novel Compound Mutations Causing Resistance to Multiple Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Open
We report a novel nilotinib resistant BCR-ABL compound mutation (K245N along with G250W mutation) which impacts structural modification in BCR-ABL mutant protein leading to drug resistance. As compound mutations pose a new threat by causin…
View article: Management of hematological malignancies during the COVID-19 pandemic
Management of hematological malignancies during the COVID-19 pandemic Open
Patients with hematological malignancies (HM) appear to be at increased risk of acquiring COVID-19 infection and its complications. General measures to protect patients with HM from COVID-19 include limiting exposure of patients to medical…
View article: Eradication of prior-to-treatment compound BCR-ABL mutations by interferon-alpha in chronic myeloid leukemia: Long-term follow-up studies and review of literature
Eradication of prior-to-treatment compound BCR-ABL mutations by interferon-alpha in chronic myeloid leukemia: Long-term follow-up studies and review of literature Open
BACKGROUND: Although tyrosine kinase inhibitors (TKIs) are the gold standard in clinical management of chronic myeloid leukemia, it is not feasible to use these drugs in at least some cases when patients are resistance to all available TKI…